Sponsor pipeline

Johnson & Johnson / Janssen clinical trial pipeline

Get alerts when Johnson & Johnson / Janssen's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-20

What changed in the last 30 days

48 trials changed in the last 30 days: 0 stopped, 9 with notable changes, 39 with minor changes only.

  1. Notable

    TRIlogy-7 · Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) · NDMM For Whom Stem Cell Transplant is Not Planned

    Recruitment opened

    Also in this update: Trial sites expanded: 0 → 19 locations; and 1 more change in the last 30 days

    Janssen Research & Development, LLCPhase 3 NCT07665450 Registry history of NCT07665450 on ClinicalTrials.gov (opens the registry)

  2. Notable

    Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) · Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

    Results posted: Sep 28, 2026

    Janssen Research & Development, LLCPhase 3 NCT04899336 Registry history of NCT04899336 on ClinicalTrials.gov (opens the registry)

Show 39 trials with minor changes only
  1. Minor

    JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma

    Enrollment increased: 240 → 276 participants

    And 2 more changes in the last 30 days

    Janssen Research & Development, LLCPhase 1 NCT06768489 Registry history of NCT06768489 on ClinicalTrials.gov (opens the registry)

  2. Minor

    MajesTEC-3 · Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) · Relapsed or Refractory Multiple Myeloma

    Primary completion moved earlier from Sep 15, 2025 to Aug 1, 2025

    Janssen Research & Development, LLCPhase 3 NCT05083169 Registry history of NCT05083169 on ClinicalTrials.gov (opens the registry)

  3. Minor

    MARIPOSA-2 · Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy · Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

    Study completion pushed from Nov 30, 2027 to Jul 3, 2028

    Janssen Research & Development, LLCPhase 3 NCT04988295 Registry history of NCT04988295 on ClinicalTrials.gov (opens the registry)

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-10-01 NCT07851207 A Study to Assess Guselkumab in Participants With Moderate-to-Severe Inflammatory Bowel… Not Yet Recruiting
2026-09-21 NCT07832292 A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer Phase 2 Recruiting

Active trials by phase

Phase 1
47
Phase 1/2
12
Phase 2
30
Phase 2/3
7
Phase 3
71
Phase 4
6
Not charted: 33 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials, top 10 of 32

Get alerts when Johnson & Johnson / Janssen's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free